News
Microdose GLP-1 news
Latest — updated August 10, 2026
Every item dated and verified against the publisher’s own pages; the running desk file.
Wegovy pill 4 mg offer ends August 31
NovoCare's published pricing keeps the 1.5 mg oral dose at $149/month but steps the 4 mg dose from $149 to $199 after August 31, 2026 — the entry price of the approved-pill lane shifts in three weeks.
503B exclusion comment window closes; no final rule yet
The FDA's April 30 proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list reached the end of its extended comment period in early August. Finalization would foreclose bulk compounding even in a future shortage; patient-specific 503A prescribing is unaffected.
Brand 12-month subscriptions hold at $249/month
Ro, WeightWatchers, and LifeMD continue the first multi-month brand Wegovy plans launched March 31 — $329/$299/$249 on 3/6/12-month commitments — the narrowest brand-vs-compounded gap on record.
Wegovy HD (7.2 mg) cash price: $399/month
The higher-dose semaglutide approved March 19 (≈20.7% average weight loss in STEP UP) sells through NovoCare at $399/month — $50 over standard pens; the $199 two-fill intro continues through December 31.
Dose-response confirmed at the top: 7.2 mg data
STEP UP quantified the trade: greater weight loss at 7.2 mg with more dose reductions for adverse events (18.5% vs 12.4% at 2.4 mg) and a dysesthesia signal (~1 in 5) — the cleanest evidence yet that effect and tolerability both ride the dose curve.
Tirzepatide–B12 adduct finding keeps additive formulations under scrutiny
2026 laboratory work showing tirzepatide chemically bonds with added vitamin B12 — forming a molecule absent from any approved product — continues to anchor FDA concern about differentiated compounded formulations.
Orforglipron widens the approved oral lane
April's approval of the first oral small-molecule GLP-1 (~12% average loss at top dose, no food/water timing rules) adds a second approved pill and new price pressure below the injectables.
No shortage, no bulk pathway: the supply logic inverts
With both molecules long off the shortage list and the 503B exclusion pending, compounded supply narrows to patient-specific 503A channels — making named pharmacies and month-to-month billing the defensive defaults for any compounded program in 2026.
Seven monitored categories; items publish only when newsworthy and sourced.
Microdose GLP One tracks GLP-1 microdosing developments across seven categories: research, regulation, provider pricing, pharmacy alerts, access and insurance, shortage and supply, and the provider market. Each category publishes an item only when it is genuinely newsworthy and tied to a primary source with a date — we do not manufacture freshness.
Category pages are live as monitored status pages; individual items index only when sourced to a primary record. This avoids fake freshness and soft-404 news shells.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.